PRESS RELEASE: Carina Biotech to Present Preclinical Data at 8th CAR-TCR Summit

2023-08-25T11:07:49+09:30August 25th, 2023|News, Press Release|

ADELAIDE, AUSTRALIA, August 21, 2023 Carina Biotech to Present Preclinical Data Evaluating LGR5-Targeted CAR-T Cell Therapy in Human Cancer Models at 8th CAR-TCR Summit LGR5 is expressed, both in vitro

Carina receives ‘Safe to proceed’ letter for Phase 1/2a clinical trial of CNA3103

2023-05-02T13:29:34+09:30January 24th, 2023|Cancer Trial, News|

PRESS RELEASE Tuesday, January 24, 2023 Carina Biotech Receives FDA “Safe to Proceed” Letter for IND Application for Phase 1/2a Clinical Trial of LGR5-Targeted CAR-T Cell Therapy Candidate for Treatment

Carina Biotech appoints Cell Therapies to undertake manufacture of LGR5 CAR-T cells for clinical trial

2022-05-31T11:04:59+09:30May 31st, 2022|News, Uncategorised|

Carina Biotech is pleased to announce that it has appointed Australian organisation Cell Therapies to undertake Good Manufacturing Processes (GMP) manufacture of its LGR5 CAR-T cells for a first-in-human clinical

Go to Top